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• Artemisinic acid (AA) is a precursor of the antimalarial drug artemisinin, which is
originally extracted from Artemisia annua.
• In plants it is present in short supply and its chemical production is costly and difficult.
• Climate dependence could be avoided if the metabolic pathway was moved from A.
annua to Saccharomyces cerevisiae.
• Reviews (PubMed).
• Scientific research publications (PubMed).
• Patents (Espacenet).
• Company’s Websites.
• Comments from experts.
Genetic engineering tools
• Plasmids. Yeast Integrative plasmids (YIp) have been
used for integration of constructions containing genes
from endogenous mevalonate pathway. On the other
hand, Yeast Episomal plasmids (YEp) have been used
for high-level expression of heterologous enzymes
(ADS, CYP71AV1 and CPR).
• Markers. Auxotrophic genetic markers have been used
for strain selection (LEU2, URA3 and HIS3).
• Promoters. Galactokinase promoters (PGAL1 and PGAL10)
have been used for gene overexpression and the
native promoter of the erg9 gene has been
substituted by a methionine-repressible promoter for
ERG9 repression.
• Different strategies and tools have been employed to engineer the mevalonate pathway of S. cerevisiae for FPP overproduction and
artemisinic acid production. Furthermore, they have increased the efficiency of amorphadiene conversion to artemisinic acid and have
paved the way for a viable large-scale production of artemisinin.
• Use of synthetic biology and metabolic engineering have allowed the assembly of the complete pathway for artemisinic acid production in
a S. cerevisiae strain.
• Similarities in genetic modifications between valencene, bisabolene, farnesene and artemisinic acid strain producers support that S.
cerevisiae could be used as a cell factory platform for sesquiterpenes production.
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1. FPP overproduction
Direct overexpression of all genes from the
mevalonate pathway
ERG9 repression by copper addition
2. Artemisinic Acid production
Heterologous expression of codon-optimised ADS
and CYP71AV1
Integration and repression of codon-optimised CPR1
Integration and overexpression of three additional
codon-optimised plant enzymes (CYB5, ADH1 and
ALDH1)
1. FPP overproduction:
Direct overexpression of tHMGR and ERG20
by GAL induction
Indirect expression by UPC2-1 overexpression
ERG9 repression by methionine addition
2. Artemisinic Acid production:
Heterologous expression of codon-optimised
ADS
Heterologous expression of CYP71AV1 and
CPR1
Bisabolene Farnesene
(+)-Nootkatone(+)-Valencene
Genetic engineering tools
• Cassettes. Expression cassettes were obtained with
overlapping PCR. These cassettes contained
homologous fragments for targeted integration.
• Markers. Drug resistance markers (dsdA, natA, kanA
and hphA) and auxotrophic markers (LEU2, URA3 and
HIS3) have been used for strain selection.
• Promoters. PGAL1 and PGAL10 have been used for the
overexpression of all genes from the mevalonate
pathway. A strong promoter (PGAL7) induced CYB5,
ALDH1 and ADH1 overexpression and a weaker
promoter (PGAL3), reduced CPR expression. Deletion of
gal80 allowed constitutive expression of all galactose-
regulated enzymes. The MET3 promoter was
replaced with the copper-regulated CTR3 promoter.
• Evaluate different modifications carried out to convert S.
cerevisiae into a cell factory for artemisinic acid production.
• Examine whether those modifications could be broadened to
produce other sesquiterpenes.
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Strain Y285 Y301 Y657 Y692 Y1368 Y1283
ERG9 Repression PMET3 PCTR3
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CYB5 Expression No Yes
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Sanofi announced in April, 2013 the launch of
large-scale production of semisynthetic
artemisinin. They plan to produce, on average,
from 50 to 60 tons from 2014 onwards in order
to guarantee enough supply for up to 150 million
ACT treatments.
Success of genetic modifications to
increase the FPP pool reinforces the
feasibility of using S. cerevisiae as a
chassis organism for sesquiterpenes
production.
Valencene synthase
8-epicedrol synthase
Germacrene A synthase
Patchoulol synthase
…
Results
Original metabolic engineering strategy
Optimised metabolic engineering strategy
S. cerevisiae
Figure 2. Amorphadiene production in shake-flask cultures by different engineered strains
(A) and sequential steps to engineer the artemisinic acid-producing strain1 (B) (Adapted from
Ro et al).
Figure 4. Production of artemisinic acid and other pathway intermediates in shake-flask
cultures by different engineered strains (A) and sequential steps to obtain each engineered
strain2 (B) (Adapted from Paddon et al).
Complete assembly of AA 
biosynthetic pathway
Overall production: Up to 100 mg·L-1 of  artemisinic acid
Overall production: 25 g·L-1 of artemisinic acid
Figure 1. Overview of the genetic modifications carried out in the first  artemisinic acid –
producing S. cerevisiae strain1 (Adapted from Ro et al).
Figure 3. Overview of the genetic modifications  to optimise AA production2.
Simple 
sugars
Figure 5. Schematic representation of S. cerevisiae as a chassis organism for sesquiterpenes production.
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Industrial interest: Flavours, fragrances and insect repellents.  
Industrial interest: Fuel alternatives. Farnesene can also be converted
into a wide range of products such as cosmetics, perfumes, detergents
and industrial lubricants.
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Artemisinic Aldehyde
Artemisinic Alcohol
Amorphadiene
Artemisinic Acid
